Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Search stocks
Aarti Industries Ltd

| Q4 FY26 Earnings Conference Call

NEUTRAL SENTIMENT

Report Source

⬤11th May 26

Summary : Aarti Industries demonstrated resilience in Q4 FY26 amidst global headwinds, achieving strong growth, securing new contracts, and advancing strategic initiatives for future growth.

Management Perspective neutral : The quarter was defined by a complex and dynamic global landscape, but performance demonstrated inherent resilience. Management expressed cautious optimism for FY26-27, acknowledging significant challenges while highlighting efforts to mitigate impacts and focus on long-term growth.

Concall Report Analysis & Insights

Business Overview

  1. Q4 FY26 revenue grew 9% Y-o-Y to INR2,422 crore, with EBITDA up 29% and PAT up 43%.
  2. Full year FY26 revenue increased 12% to INR9,018 crore, EBITDA 15%, and PAT 27%.
  3. Company demonstrated resilience with a diversified, cost-competitive product portfolio despite global volatility.
  4. Secured two long-term contracts: a backward integration initiative and a $150 million multiyear supply agreement.
  5. Recognized with the 2026 Gallup Exceptional Workplace Award, reinforcing global manufacturing position.

Future Growth Prospects

  1. Zone IV projects are expected to be commissioned in a phased manner during the current financial year.
  2. Multipurpose plant and PEDA plants are under commissioning trials and should come on stream soon.
  3. Capex for FY27 is projected at INR700-800 crore, focusing on high-growth, niche projects.
  4. Augene JV is on track for commissioning in H1FY27, initially focusing on agrochemicals and coatings.
  5. New partnerships and JVs are expected to contribute meaningfully to future business growth.

Management Insights

  1. Q4 FY26 performance demonstrated the inherent resilience of our diversified and cost-competitive product portfolio.
  2. We proactively redirected volumes from the Middle East to other geographies, minimizing impact.
  3. The company is making a strategic shift towards deeper integration, enhanced earnings visibility, and improved capital efficiency.
  4. FY27 capex will be optimized, focusing on high-growth initiatives to maximize returns.
  5. We maintain cautious optimism for FY26-27, supported by improved capacity utilization and strong order visibility.

Signs of Skepticism

  1. Management was hesitant to provide specific revenue/margin potential for new projects, citing interlinked products and dynamic pricing.
  2. Uncertainty remains regarding the stabilization of raw material prices and the Middle East geopolitical situation.
  3. Acknowledged a 3-4 month delay in Zone IV project commissioning due to labor constraints and elections.
  4. Working capital requirements remain dynamic, dependent on export regions and transit times.

Risk Factors

  1. Geopolitical tensions in the Middle East are causing disruptions across global supply chains and trade flows.
  2. Prices of key raw materials like benzene, sulfur, and methanol increased by over 60%.
  3. Elevated freight rates are increasing the cost of global trade and other expenses.
  4. Curtailment of volumes from the Middle East created significant supply chain issues.
  5. Ongoing volatility in refining product margins and supply chain risks pose near-term challenges.

Good To Know

  1. The company recorded an FX gain of approximately INR10 crore in Q4 FY26.
  2. Interest costs included an INR39 crore revaluation loss on a long-term foreign currency loan.
  3. Net debt, after adjusting for recent cash movements, is around INR4,300 crore.
  4. Contract labor availability in the region for capex execution reduced by 35%.
  5. The company targets working capital days of 55-60 and a future tax rate of 9-15%.

Key Drivers

  1. New long-term contracts enhance visibility.
  2. Zone IV projects commissioning soon.
  3. Capacity utilization levels improving.
  4. Strategic partnerships advancing well.

Key Analyst Discussions

Competitive Environment

  1. Company pushed volumes to improve utilization; some value chains are healthy, others need long-term solutions.
  2. Pricing recovery is seen in pockets; broader recovery depends on Chinese industry actions.
  3. China's anti-involution stance has improved margin profiles, especially in NCB.
  4. Nitration-related incidents in China are expected to increase regulatory scrutiny, benefiting safer operators.
  5. Company's product portfolio is significantly different from those involved in recent China accidents.

Market Trends & Consumer Behavior

  1. 9-10% of revenue comes from the Middle East, with volumes actively being rerouted to other geographies.
  2. MMA performance is complex, influenced by multiple factors including naphtha-gasoline spread and raw material costs.
  3. The impact of the West Asia war on energy revenue depends on how quickly the situation stabilizes.
  4. Domestic market growth is offsetting global demand pressure in discretionary portfolios.
  5. Global GDP trends could pose a potential risk to discretionary spending, which the company monitors.

Financial Highlights

  1. Q4 inventory gain was a mixed bag, with some FX gain offsetting raw material price increases.
  2. FY26 capex was INR1,125 crore as guided; FY27 capex is projected at INR700-800 crore.
  3. Increased working capital was attributed to materials in transit and raw material price impact.
  4. A 22% increase in other expenses was primarily due to elevated freight rates and higher export volumes.
  5. The INR39 crore FX revaluation loss resulted from rupee depreciation on an unhedged $87 million loan.

Product Composition

  1. The dye segment, representing 10-11% of revenue, shows mixed trends with global pressure offset by domestic growth.
  2. Agrochemical margin pressure depends on the evolution and conduct of the Chinese industry.
  3. The Bayer contract asset is 50% utilized for Dicamba, with steady volumes and expected better utilization.
  4. The company aims to optimize volumes and spreads to ensure manufacturing assets run at healthy utilization levels.

Strategic Considerations

  1. Zone IV projects will commission in phases, with initial revenue expected from Q2 FY27.
  2. FY27 capex will primarily fund Zone IV completion, new long-term contracts, and asset maintenance.
  3. Backward integration will provide an additional fixed margin for the remaining 15-year contract period.
  4. Momentum on new partnerships and JVs continues despite the West Asia conflict, driven by demand for robust supply chains.
  5. The company's ability to deliver reliable and safe operations in complex chemistries is a key value proposition for partnerships.